

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION N
10/611,914	07/03/2003	Eyal Talor	CS-120	5597
7590 11/10/2004			EXAMINER	
SHERMAN & SHALLOWAY			NICKOL, GARY B	
413 North Washington Street Alexandria, VA 22314		•	ART UNIT	PAPER NUMBER
1110/14/14/14/			1642	
,			1642 DATE MAIL ED: 11/10/200	,

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/611,914	TALOR, EYAL
Office Action Summary	Examiner	Art Unit
	Gary B. Nickol Ph.D.	1642
The MAILING DATE of this communication		
Period for Reply	·	
A SHORTENED STATUTORY PERIOD FOR F THE MAILING DATE OF THIS COMMUNICAT - Extensions of time may be available under the provisions of 37 C after SIX (6) MONTHS from the mailing date of this communicati - If the period for reply specified above is less than thirty (30) days - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, by Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	TON. CFR 1.136(a). In no event, however, may a relion. s, a reply within the statutory minimum of thirty period will apply and will expire SIX (6) MONT a statute, cause the application to become ABA	ply be timely filed (30) days will be considered timely. HS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
Status		
 1) ⊠ Responsive to communication(s) filed on 2a) ⊠ This action is FINAL. 2b) □ 3) ☐ Since this application is in condition for all closed in accordance with the practice un 	This action is non-final. Ilowance except for formal matte	•
Disposition of Claims		
 4) Claim(s) 1-41 is/are pending in the application 4a) Of the above claim(s) 1-23 and 28-41 5) Claim(s) is/are allowed. 6) Claim(s) 24-27 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and claim(s) are subject to restriction are subject to restriction and claim(s) are subject to restriction are subject to restriction are subject to restriction are subject to restriction and claim(s) are subject to restriction are subject to restriction are subject to restriction. 	is/are withdrawn from considera	ition.
Application Papers		
9) The specification is objected to by the Exact 10) The drawing(s) filed on is/are: a) Applicant may not request that any objection to Replacement drawing sheet(s) including the county of the oath or declaration is objected to by the second	accepted or b) objected to be to the drawing(s) be held in abeyand correction is required if the drawing(s	ce. See 37 CFR 1.85(a). s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119	,	
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of: 1. Certified copies of the priority docu 2. Certified copies of the priority docu 3. Copies of the certified copies of the application from the International B * See the attached detailed Office action for	iments have been received. Iments have been received in Apere priority documents have been received in Rule 17.2(a)).	plication No eceived in this National Stage
	<i>)</i>	
Attachment(s)		
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-94 Information Disclosure Statement(s) (PTO-1449 or PTO/94) Paper No(s)/Mail Date 	Paper No(s)	Immary (PTO-413) /Mail Date formal Patent Application (PTO-152)

Page 2

Application/Control Number: 10/611,914

Art Unit: 1642

Re: Talor, E.

Date of priority: 7-3-03

Response to Amendment

The Amendment filed 09-03-04 in response to the Office Action of 08-19-04 is

acknowledged and has been entered.

Claims 1-41 are pending.

Claims 1-23 and 28-41 have been withdrawn from further consideration by the examiner

under 37 CFR 1.142(b) as being drawn to non-elected inventions.

Claims 24-27 are currently under consideration.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a

prior Office Action.

Specification

The specification is no longer objected to because applicants have noted (Remarks, page

3) that the changes to the ratio ranges were indeed typographical as the upper and lower bounds

of the ranges did not mathematically support the ranges on pages 15 and 26 of the specification.

For example, applicants note that if the amendments are not entered then the disclosed preferred

range of 3.0 +/-0.18 is outside the preferred range because 2.87 is higher than the lower limit of

Application/Control Number: 10/611,914

Art Unit: 1642

the preferred range. Applicants further note that the remaining changes to the ratio ranges are similarly supported by the specification.

New Rejections:

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 24-27 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Newly amended claims 24 and 26 are now limited to cytokine mixtures "with the proviso that IL-12 is present in only trace quantities". However, the only support in the specification for a cytokine mixture that contains trace amounts of IL-12 is to the trademarked brand of cytokines termed Multikine® (page 12, line 30). The fact that one particular and distinct brand of packaged cytokines contains trace amounts of IL-12 does not provide sufficient direction and guidance to the features currently claimed. Hence, applicants appear to be claiming a subgenus of cytokine compositions <u>not</u> supported by the specification as originally filed. It is noted that a generic or a sub-generic disclosure cannot support a species unless the species is specifically

Application/Control Number: 10/611,914

Art Unit: 1642

described. It cannot be said that a subgenus is necessarily described by a genus encompassing it and a species upon which it reads. See In re Smith 173 USPQ 679, 683 (CCPA 1972) and MPEP 2163.05. Hence, the instant claims now recite limitations, which were not clearly disclosed in the specification as filed, and now change the scope of the instant disclosure as-filed. Such limitations recited in the present claims, which did not appear in the specification, as filed, introduce new concepts and violate the description requirement of the first paragraph of 35 U.S.C. 112.

Applicant is required to cancel the new matter in the response to this Office action. Alternatively, applicant is invited to provide sufficient written support for the limitations indicated above. See MPEP 714.02 and 2163.06.

All other rejections and or objections are withdrawn in view of applicant's amendments and arguments there to.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

MONTHS of the mailing date of this final action and the advisory action is not mailed until after

Application/Control Number: 10/611,914

Art Unit: 1642

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary B. Nickol Ph.D. whose telephone number is 571-272-0835. The examiner can normally be reached on M-Th, 8:30-5:30; alternate Fri., 8:30-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gary B. Nickol Ph.D. Primary Examiner Art Unit 1642

GBN

GARY NICKOL PRIMARY EXAMINER